» Articles » PMID: 39375173

Adverse Events After Colonoscopy in a Randomised Colorectal Cancer Screening Trial

Overview
Specialty Gastroenterology
Date 2024 Oct 7
PMID 39375173
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Colonoscopy-related adverse events increase the burden of colorectal cancer (CRC) screening. This cross-sectional study evaluates adverse events during and after colonoscopy in a large, randomised CRC screening trial in Norway comparing sigmoidoscopy to immunochemical testing for faecal blood.

Methods: We included all individuals who underwent colonoscopy at two screening centres between 2012 and 2020. From medical records, we retrieved data on adverse events during and within 30 days after colonoscopy and classified them according to the American Society for Gastrointestinal Endoscopy lexicon for endoscopic adverse events. Multivariable logistic regression models were fitted to identify risk factors for adverse events.

Results: Of the 10 244 included individuals, 242 (2.4%) had at least one adverse event that was possibly, probably, or definitively related to the colonoscopy. 188 (1.8%) had mild adverse events, 50 (0.49%) had moderate, 3 (0.03%) had severe, and 1 had a fatal adverse event. The most frequent adverse events were lower gastrointestinal bleeding (0.86%), abdominal pain (0.48%), vasovagal reaction (0.39%), postpolypectomy syndrome (0.20%), and perforation (0.08%). 23 (0.22%) individuals had non-gastrointestinal adverse events. Risk factors associated with adverse events were older age, female sex, screening centre, anticoagulant therapy, number of polypectomies, size of lesion removed, presence of proximal lesion, and adenocarcinoma. Adverse event rates per endoscopist ranged from 0% to 4.9%.

Conclusion: Adverse events after colonoscopy of screening positives occurred in about 2 out of 100 procedures. Three-quarters of events were mild. Awareness of risk factors may help endoscopists to mitigate the risk.

Trial Registration Number: NCT01538550.

References
1.
Mazurek M, Murray A, Heitman S, Ruan Y, Antoniou S, Boyne D . Association Between Endoscopist Specialty and Colonoscopy Quality: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(9):1931-1946. DOI: 10.1016/j.cgh.2021.08.029. View

2.
Li S, Seedher T, Sharples L, Benton S, Mathews C, Gabe R . Impact of changes to the interscreening interval and faecal immunochemical test threshold in the national bowel cancer screening programme in England: results from the FIT pilot study. Br J Cancer. 2022; 127(8):1525-1533. PMC: 9553931. DOI: 10.1038/s41416-022-01919-y. View

3.
Lin J, Perdue L, Henrikson N, Bean S, Blasi P . Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325(19):1978-1998. DOI: 10.1001/jama.2021.4417. View

4.
Mikkelsen E, Thomsen M, Tybjerg J, Friis-Hansen L, Andersen B, Jorgensen J . Colonoscopy-related complications in a nationwide immunochemical fecal occult blood test-based colorectal cancer screening program. Clin Epidemiol. 2018; 10:1649-1655. PMC: 6239110. DOI: 10.2147/CLEP.S181204. View

5.
Arana-Arri E, Imaz-Ayo N, Fernandez M, Idigoras I, Bilbao I, Bujanda L . Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a population-based program: A nested case-control study. United European Gastroenterol J. 2018; 6(5):755-764. PMC: 6068784. DOI: 10.1177/2050640618756105. View